USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
14 02 2023
Historique:
received: 29 03 2022
revised: 14 12 2022
accepted: 15 12 2022
pubmed: 21 1 2023
medline: 18 2 2023
entrez: 20 1 2023
Statut: ppublish

Résumé

Adenomatous polyposis coli (APC) mutation is the hallmark of colorectal cancer (CRC), resulting in constitutive WNT activation. Despite decades of research, targeting WNT signaling in cancer remains challenging due to its on-target toxicity. We have previously shown that the deubiquitinating enzyme USP7 is a tumor-specific WNT activator in APC-truncated cells by deubiquitinating and stabilizing β-catenin, but its role in gut tumorigenesis is unknown. Here, we show in vivo that deletion of Usp7 in Apc-truncated mice inhibits crypt hyperproliferation and intestinal tumor development. Loss of Usp7 prolongs the survival of the sporadic intestinal tumor model. Genetic deletion, but not pharmacological inhibition, of Usp7 in Apc

Identifiants

pubmed: 36669491
pii: S2213-6711(22)00605-1
doi: 10.1016/j.stemcr.2022.12.013
pmc: PMC9968985
pii:
doi:

Substances chimiques

Ubiquitin-Specific Peptidase 7 EC 3.4.19.12
beta Catenin 0
USP7 protein, human EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-584

Subventions

Organisme : Medical Research Council
ID : MC_UP_1202/7
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CC2141
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2141
Pays : United Kingdom
Organisme : Wellcome Trust
ID : CC2141
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interests The authors declare no competing interests.

Références

BMC Cancer. 2010 Jul 22;10:389
pubmed: 20649969
Cancer Res. 2011 Jan 1;71(1):197-205
pubmed: 21199802
Hum Mutat. 1993;2(6):425-34
pubmed: 8111410
Nat Med. 2004 Aug;10(8):789-99
pubmed: 15286780
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22
pubmed: 22753465
Nat Commun. 2019 Sep 13;10(1):4184
pubmed: 31519875
Int J Dev Biol. 2004;48(5-6):377-86
pubmed: 15349813
Cell. 2015 Jun 18;161(7):1539-1552
pubmed: 26091037
Cell. 1991 Aug 9;66(3):601-13
pubmed: 1678319
Nature. 2007 Oct 25;449(7165):1003-7
pubmed: 17934449
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Science. 1991 Aug 9;253(5020):661-5
pubmed: 1651562
Nat Chem Biol. 2018 Feb;14(2):118-125
pubmed: 29200206
Exp Mol Med. 2020 Feb;52(2):183-191
pubmed: 32037398
Curr Opin Genet Dev. 1995 Feb;5(1):66-71
pubmed: 7749328
Cell Chem Biol. 2017 Dec 21;24(12):1501-1512.e5
pubmed: 29056420
Cancer Res. 2007 Jun 1;67(11):5371-9
pubmed: 17545618
Science. 1992 May 1;256(5057):668-70
pubmed: 1350108
Nature. 2017 Oct 26;550(7677):481-486
pubmed: 29045389
Cell Death Dis. 2013 Oct 17;4:e867
pubmed: 24136231
Cell. 2012 Jun 8;149(6):1245-56
pubmed: 22682247
Nature. 2017 Oct 26;550(7677):534-538
pubmed: 29045385
Nature. 2009 Oct 1;461(7264):614-20
pubmed: 19759537
Cell. 1991 Aug 9;66(3):589-600
pubmed: 1651174
EMBO J. 1997 Jul 1;16(13):3797-804
pubmed: 9233789
Science. 1991 Aug 9;253(5020):665-9
pubmed: 1651563
EMBO J. 1999 May 4;18(9):2401-10
pubmed: 10228155
Cancer Res. 2012 Jun 1;72(11):2822-32
pubmed: 22440753
Cell. 2002 Mar 22;108(6):837-47
pubmed: 11955436
Cell Death Differ. 2011 Aug;18(8):1366-75
pubmed: 21350561
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Genes Dev. 2004 Jun 15;18(12):1385-90
pubmed: 15198980
Cell Rep. 2017 Oct 17;21(3):612-627
pubmed: 29045831
Science. 1997 Oct 3;278(5335):120-3
pubmed: 9311916
Mol Cell. 2005 May 27;18(5):565-76
pubmed: 15916963
Am J Physiol Cell Physiol. 2015 Oct 15;309(8):C511-21
pubmed: 26289750
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Chem Biol. 2009 Feb;5(2):100-7
pubmed: 19125156
Clin Cancer Res. 2017 Dec 15;23(24):7490-7497
pubmed: 28954784
Cancer Res. 2013 May 15;73(10):3132-44
pubmed: 23539443
Semin Immunopathol. 2013 Mar;35(2):229-44
pubmed: 23161445
Gynecol Oncol. 2019 Aug;154(2):294-301
pubmed: 31174889
Nature. 2002 Apr 11;416(6881):648-53
pubmed: 11923872
Br J Pharmacol. 2017 Dec;174(24):4611-4636
pubmed: 28910490

Auteurs

Laura Novellasdemunt (L)

Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Anna Kucharska (A)

Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Anna Baulies (A)

Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Colin Hutton (C)

Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Georgios Vlachogiannis (G)

Centre for Molecular Pathology, the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

Dimitra Repana (D)

Cancer Systems Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Andrew Rowan (A)

Cancer Evolution and Genome Instability Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

A Suárez-Bonnet (A)

Pathobiology and Population Sciences, Royal Veterinary College, Hatfield AL9 7TA, UK; Experimental Histopathology, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Francesca Ciccarelli (F)

Cancer Systems Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Nicola Valeri (N)

Centre for Molecular Pathology, the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

Vivian S W Li (VSW)

Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: vivian.li@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH